Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
27.35 USD | +4.95% | +7.23% | +203.09% |
May. 08 | Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Treatment of Myotonic Dystrophy Type 1 | MT |
May. 08 | Avidity's Lead Program Gets FDA Breakthrough Designation | DJ |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+203.09% | 2.49B | |
-3.35% | 88.91B | |
+2.76% | 41.25B | |
-14.53% | 31.99B | |
+50.51% | 24.73B | |
-14.93% | 15.54B | |
-39.93% | 12.07B | |
-9.08% | 12.05B | |
-15.16% | 12.02B | |
+6.22% | 8.84B |
- Stock Market
- Equities
- RNA Stock
- News Avidity Biosciences, Inc.
- Transcript : Avidity Biosciences, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 01